BRPI0606437A - composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta - Google Patents
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaquetaInfo
- Publication number
- BRPI0606437A BRPI0606437A BRPI0606437-0A BRPI0606437A BRPI0606437A BR PI0606437 A BRPI0606437 A BR PI0606437A BR PI0606437 A BRPI0606437 A BR PI0606437A BR PI0606437 A BRPI0606437 A BR PI0606437A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000002172 P2Y12 inhibitor Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500140A GB0500140D0 (en) | 2005-01-06 | 2005-01-06 | Novel compounds |
| GB0521484A GB0521484D0 (en) | 2005-10-21 | 2005-10-21 | Novel compounds |
| PCT/SE2006/000010 WO2006073361A1 (en) | 2005-01-06 | 2006-01-04 | Novel pyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606437A true BRPI0606437A (pt) | 2008-03-11 |
Family
ID=36647772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606437-0A BRPI0606437A (pt) | 2005-01-06 | 2006-01-04 | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090227555A2 (enExample) |
| EP (1) | EP1836189A1 (enExample) |
| JP (1) | JP2008526840A (enExample) |
| KR (1) | KR20070107024A (enExample) |
| AR (1) | AR055554A1 (enExample) |
| AU (1) | AU2006204159A1 (enExample) |
| BR (1) | BRPI0606437A (enExample) |
| CA (1) | CA2594255A1 (enExample) |
| IL (1) | IL183961A0 (enExample) |
| MX (1) | MX2007008237A (enExample) |
| NO (1) | NO20073101L (enExample) |
| RU (1) | RU2007129779A (enExample) |
| TW (1) | TW200626593A (enExample) |
| UY (1) | UY29325A1 (enExample) |
| WO (1) | WO2006073361A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007008140A1 (en) * | 2005-07-13 | 2007-01-18 | Astrazeneca Ab | New pyridine analogues |
| WO2008004944A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline form ii |
| CN101506193A (zh) * | 2006-07-04 | 2009-08-12 | 阿斯利康(瑞典)有限公司 | 新吡啶类似物 |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
| WO2008004945A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline forms i and ii |
| TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
| UY30866A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolos y aplicaciones (519) |
| AR064867A1 (es) * | 2007-01-12 | 2009-04-29 | Astrazeneca Ab | Analogos de piridina viii 518 |
| UY30867A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos analogos de piridina vii 543 |
| CA2690243A1 (en) * | 2007-06-18 | 2008-12-24 | Sanofi-Aventis | Pyrrole derivatives as p2y12 antagonists |
| WO2009011627A1 (en) * | 2007-07-13 | 2009-01-22 | Astrazeneca Ab | Pyridine compounds and their use as p2y12 antagonists |
| AR074628A1 (es) * | 2008-07-07 | 2011-02-02 | Astrazeneca Ab | Derivados de piridina 2- amino-6-alquil sustituidos utiles como inhibidores de p2y12 308 |
| WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP2014051434A (ja) * | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
| EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| HK1206716A1 (en) | 2012-08-21 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Novel pyridine derivatives |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| AU2023388768A1 (en) | 2022-12-06 | 2025-05-01 | Idorsia Pharmaceuticals Ltd | Crystalline adipic acid salt form of a ccr6 antagonist |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2220055C (en) * | 1995-05-08 | 2001-04-24 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
| JP2001526178A (ja) * | 1997-08-28 | 2001-12-18 | メルク エンド カムパニー インコーポレーテッド | ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤 |
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| ATE309999T1 (de) * | 2000-02-04 | 2005-12-15 | Portola Pharm Inc | Blutplättchen-adp-rezeptor-inhibitoren |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| US7452870B2 (en) * | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7018985B1 (en) * | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| FR2820057A1 (fr) * | 2001-01-30 | 2002-08-02 | Ct De Transfert De Technologie | Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane |
| AU2002336462A1 (en) * | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| AR037097A1 (es) * | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7749981B2 (en) * | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US7504497B2 (en) * | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| WO2006012226A2 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| CN101506193A (zh) * | 2006-07-04 | 2009-08-12 | 阿斯利康(瑞典)有限公司 | 新吡啶类似物 |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
| JP2009542643A (ja) * | 2006-07-04 | 2009-12-03 | アストラゼネカ アクチボラグ | 新規ピリジン類似体 |
-
2006
- 2006-01-04 BR BRPI0606437-0A patent/BRPI0606437A/pt not_active IP Right Cessation
- 2006-01-04 US US11/813,289 patent/US20090227555A2/en not_active Abandoned
- 2006-01-04 AU AU2006204159A patent/AU2006204159A1/en not_active Abandoned
- 2006-01-04 MX MX2007008237A patent/MX2007008237A/es not_active Application Discontinuation
- 2006-01-04 KR KR1020077018077A patent/KR20070107024A/ko not_active Withdrawn
- 2006-01-04 WO PCT/SE2006/000010 patent/WO2006073361A1/en not_active Ceased
- 2006-01-04 EP EP06700210A patent/EP1836189A1/en not_active Withdrawn
- 2006-01-04 JP JP2007550328A patent/JP2008526840A/ja active Pending
- 2006-01-04 RU RU2007129779/04A patent/RU2007129779A/ru not_active Application Discontinuation
- 2006-01-04 CA CA002594255A patent/CA2594255A1/en not_active Abandoned
- 2006-01-05 UY UY29325A patent/UY29325A1/es unknown
- 2006-01-05 AR ARP060100040A patent/AR055554A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100677A patent/TW200626593A/zh unknown
-
2007
- 2007-06-14 IL IL183961A patent/IL183961A0/en unknown
- 2007-06-18 NO NO20073101A patent/NO20073101L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090227555A2 (en) | 2009-09-10 |
| NO20073101L (no) | 2007-07-19 |
| EP1836189A1 (en) | 2007-09-26 |
| AU2006204159A1 (en) | 2006-07-13 |
| US20090042852A1 (en) | 2009-02-12 |
| CA2594255A1 (en) | 2006-07-13 |
| WO2006073361A9 (en) | 2007-08-02 |
| MX2007008237A (es) | 2007-08-17 |
| IL183961A0 (en) | 2007-10-31 |
| TW200626593A (en) | 2006-08-01 |
| UY29325A1 (es) | 2006-08-31 |
| KR20070107024A (ko) | 2007-11-06 |
| WO2006073361A1 (en) | 2006-07-13 |
| AR055554A1 (es) | 2007-08-22 |
| JP2008526840A (ja) | 2008-07-24 |
| RU2007129779A (ru) | 2009-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0606437A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
| BRPI0713367A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| BRPI0609719B8 (pt) | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 | |
| BRPI0805826B8 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
| BRPI0908353B8 (pt) | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| BRPI0410037B8 (pt) | inibidores de fosfatidilinositol 3-cinase, sua composição farmacêutica, e seu uso | |
| BRPI0518126A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| BRPI0818533B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BRPI0606930A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente | |
| BRPI0514691A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| BRPI0720588B8 (pt) | derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase | |
| CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| BRPI0606793A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |